-
Mashup Score: 92Completion Of Pembrolizumab In advanced non-small cell Lung cancer – real world Outcomes after Two years of therapy (COPILOT) - 21 day(s) ago
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations. Pembrolizumab, an ICI directed against PD-1, has been shown in four practice changing first line phase III randomised controlled trials to improve overall survival alone, or in combination with chemotherapy, compared to chemotherapy alone in patients with advanced NSCLC1-4.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 53Real-world Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small Cell Lung Cancer - 1 month(s) ago
Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II–III NSCLC in the United States (US).
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Lung Cancer Survival Trends in the Veterans Health Administration - 2 month(s) ago
A New England Journal of Medicine (NEJM)1 report in 2020 demonstrated improving survival rates for people diagnosed with lung cancer in the United States (US).1 The study identified increasing 2-year survival rates for men (26% to 35%) and women (35% to 44%) diagnosed between 2001 and 2014. The rates of lung cancer survival increase were found to accelerate between 2013 and 2016. While these increases were observed across different racial and ethnic groups, survival rates remained inferior throughout the study period for non-Hispanic Black men and women demonstrating the persistence of lung cancer racial disparities in the US.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non–Small-Cell Lung Cancer - 2 month(s) ago
MicroabstractOur retrospective study aims to explore the clinical and genomic underpinnings of a durable response to ICI. We identify lower ECOG performance status at diagnosis, the absence of liver metastases at diagnosis and occurrence of irAEs as predictors of a prolonged response. These findings help inform on therapeutic selection and personalized discussions of benefit to patients with lung cancer.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65Durvalumab consolidation after chemoradiotherapy in elderly patients with unresectable stage III NSCLC: A real-world multicenter study - 3 month(s) ago
Approximately one-third of patients with non-small-cell lung cancer (NSCLC) are diagnosed with locally advanced disease 1. Despite advances in cancer treatment, the 5-year overall survival (OS) for this group has remained between 15% and 30%, underscoring the need for novel therapies 1,2. With the emergence of immunotherapy in cancer treatments, the PACIFIC trial demonstrated the survival benefit of durvalumab consolidation in patients with unresectable locally advanced NSCLC who experience no disease progression after concurrent chemoradiotherapy (CCRT) 3.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64Lung Cancer in Women: The Past, Present, and Future - 3 month(s) ago
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis - 3 month(s) ago
To analyze the factors associated with EGFR mutated lung cancer with leptomeningeal metastasis (LM) in the real world that affect the prognosis of patients.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93Perioperative immunotherapy for non-small cell lung cancer: practical application of emerging data and new challenges - 3 month(s) ago
Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting (Table 1). As more results read out from ongoing perioperative clinical trials, navigating treatment options will likely become increasingly complex for the practicing oncologist.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64Lung Cancer in Women: The Past, Present, and Future - 3 month(s) ago
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 64Lung Cancer in Women: The Past, Present, and Future - 3 month(s) ago
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
Real world description of pts who completed 2y of 1L pembrolizumab @ClinicalLung (n=71). In this group, RR 79%, mPFS 46.1m, 60% with #KRAS mt. 24% received local ablation for oligoprogression. 28% progressed after stopping pembro (more if PDL1 < 1%). https://t.co/RNsHzaBx6n